• Je něco špatně v tomto záznamu ?

STEP-CD study: ustekinumab use in paediatric Crohn's disease-a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN

G. Pujol-Muncunill, VM. Navas-López, O. Ledder, S. Cohen, M. Lekar, D. Turner, KL. Kolho, A. Levine, NM. Croft, J. Bronsky, DS. Shouval, A. Assa, R. Harris, F. Kiparissi, M. Aloi, NA. Afzal, C. Tzivinikos, J. Barrio, C. Norden, MJB. Vega, S....

. 2024 ; 183 (8) : 3253-3262. [pub] 20240503

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019586
E-zdroje Online Plný text

NLK ProQuest Central od 1996-01-01 do Před 1 rokem
CINAHL Plus with Full Text (EBSCOhost) od 2012-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 1997-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1996-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1996-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 1996-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1996-01-01 do Před 1 rokem

Odkazy

PubMed 38700692
DOI 10.1007/s00431-024-05588-2
Knihovny.cz E-zdroje

Ustekinumab is an effective therapy for adult Crohn's disease (CD), but data in paediatric CD patients are scarce. The aim of the study was to describe the real-life effectiveness and safety of ustekinumab in paediatric CD. This is a multicentre review of children with Crohn's disease treated with ustekinumab. The aim of our study was to describe the effectiveness and safety of ustekinumab in paediatric real-life practice. This is a study of the Paediatric IBD (inflammatory bowel disease) Porto group of ESPGHAN. Corticosteroid (CS)- and exclusive enteral nutrition (EEN)-free remission, defined as weighted Paediatric Crohn's Disease Activity Index (wPCDAI) < 12.5, and physician global assessment (PGA) were determined at weeks 12 and 52. A total of 101 children were included at a median age of 15.4 years (IQR 12.7-17.2) with a median follow-up of 7.4 months (IQR 5.6-11.8). Ninety-nine percent had received prior anti-TNF, 63% ≥ 2 anti-TNFα therapies and 22% vedolizumab. Baseline median wPCDAI was 39 (IQR 25-57.5) (71 (70%) patients with moderate-severe activity). Weeks 12 and 52 CS- and EEN-free remission were both 40.5%. Clinical response at week 6, iv induction route and older age at onset of ustekinumab treatment were predictive factors associated with clinical remission at week 12. Seven minor adverse events probably related to ustekinumab were reported. One patient died from an unrelated cause. Conclusion: Our results suggest that ustekinumab is effective and safe in children with chronically active or refractory CD. What is Known: • Ustekinumab is an effective therapy for adult moderate to severe Crohn's disease (CD). • Off-label use of ustekinumab in children is increasing especially in anti-TNF refractory CD. What is New: • Is the largest cohort of real-world use of ustekinumab in paediatric CD to date. • Clinical response at week 6, iv induction and older age at onset of ustekinumab were predictive factors associated with clinical response at week 12.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019586
003      
CZ-PrNML
005      
20241024110638.0
007      
ta
008      
241015s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00431-024-05588-2 $2 doi
035    __
$a (PubMed)38700692
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Pujol-Muncunill, Gemma $u Hospital Sant Joan de Déu, Barcelona, Spain
245    10
$a STEP-CD study: ustekinumab use in paediatric Crohn's disease-a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN / $c G. Pujol-Muncunill, VM. Navas-López, O. Ledder, S. Cohen, M. Lekar, D. Turner, KL. Kolho, A. Levine, NM. Croft, J. Bronsky, DS. Shouval, A. Assa, R. Harris, F. Kiparissi, M. Aloi, NA. Afzal, C. Tzivinikos, J. Barrio, C. Norden, MJB. Vega, S. Buderus, AF. de Valderrama, L. de Ridder, R. García-Romero, E. Medina, C. Sánchez, M. Velasco, S. Vicente, DC. Wilson, S. Naik, O. Hradsky, L. Cococcioni, J. Martin-de-Carpi
520    9_
$a Ustekinumab is an effective therapy for adult Crohn's disease (CD), but data in paediatric CD patients are scarce. The aim of the study was to describe the real-life effectiveness and safety of ustekinumab in paediatric CD. This is a multicentre review of children with Crohn's disease treated with ustekinumab. The aim of our study was to describe the effectiveness and safety of ustekinumab in paediatric real-life practice. This is a study of the Paediatric IBD (inflammatory bowel disease) Porto group of ESPGHAN. Corticosteroid (CS)- and exclusive enteral nutrition (EEN)-free remission, defined as weighted Paediatric Crohn's Disease Activity Index (wPCDAI) < 12.5, and physician global assessment (PGA) were determined at weeks 12 and 52. A total of 101 children were included at a median age of 15.4 years (IQR 12.7-17.2) with a median follow-up of 7.4 months (IQR 5.6-11.8). Ninety-nine percent had received prior anti-TNF, 63% ≥ 2 anti-TNFα therapies and 22% vedolizumab. Baseline median wPCDAI was 39 (IQR 25-57.5) (71 (70%) patients with moderate-severe activity). Weeks 12 and 52 CS- and EEN-free remission were both 40.5%. Clinical response at week 6, iv induction route and older age at onset of ustekinumab treatment were predictive factors associated with clinical remission at week 12. Seven minor adverse events probably related to ustekinumab were reported. One patient died from an unrelated cause. Conclusion: Our results suggest that ustekinumab is effective and safe in children with chronically active or refractory CD. What is Known: • Ustekinumab is an effective therapy for adult moderate to severe Crohn's disease (CD). • Off-label use of ustekinumab in children is increasing especially in anti-TNF refractory CD. What is New: • Is the largest cohort of real-world use of ustekinumab in paediatric CD to date. • Clinical response at week 6, iv induction and older age at onset of ustekinumab were predictive factors associated with clinical response at week 12.
650    _2
$a lidé $7 D006801
650    12
$a Crohnova nemoc $x farmakoterapie $7 D003424
650    12
$a ustekinumab $x terapeutické užití $7 D000069549
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a výsledek terapie $7 D016896
650    _2
$a indukce remise $7 D012074
650    _2
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Navas-López, Víctor Manuel $u Department of Paediatric Gastroenterology and Nutrition, Hospital Regional Universitario de Málaga, Málaga, Spain. victor.navas@gmail.com
700    1_
$a Ledder, Oren $u Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel
700    1_
$a Cohen, Shlomi $u Children's Hospital Tel Aviv Sourasky Medical, Tel Aviv, Israel
700    1_
$a Lekar, Marina $u Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel
700    1_
$a Turner, Dan $u Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel
700    1_
$a Kolho, Kaija-Leena $u Faculty of Medicine, University of Helsinki and Children's Hospital, University of Helsinki and HUS, Helsinki, Finland
700    1_
$a Levine, Arie $u Wolfson Medical Center, Holon, Israel
700    1_
$a Croft, Nicholas M $u The Royal London Children's Hospital, Barts Health NHS Trust, London, UK
700    1_
$a Bronsky, Jiri $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Shouval, Dror S $u Sheba Medical Center, Tel Hashomer, Israel
700    1_
$a Assa, Amit $u Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel
700    1_
$a Harris, Rachel $u Royal Hospital for Children, Glasgow, UK
700    1_
$a Kiparissi, Fevronia $u Great Ormond Street Hospital, London, UK
700    1_
$a Aloi, Marina $u Sapienza University of Rome, Rome, Italy
700    1_
$a Afzal, Nadeem Ahmad $u Southampton Children's Hospital, Southampton, UK
700    1_
$a Tzivinikos, Christos $u Al Jalila Children's Speciality Hospital, Dubai, United Arab Emirates
700    1_
$a Barrio, Josefa $u Hospital Universitario de Fuenlabrada, Madrid, Spain
700    1_
$a Norden, Christoph $u Hvidovre University Hospital, Copenhagen, Denmark
700    1_
$a Vega, Maria Jesús Balboa $u Hospital Virgen de La Macarena, Seville, Spain
700    1_
$a Buderus, Stephan $u GFO-Kliniken Bonn St. Marien-Hospital, Bonn, Germany
700    1_
$a de Valderrama, Ana Fernández $u Hospital Universitario de Burgos, Burgos, Spain
700    1_
$a de Ridder, Lissy $u Erasmus Medical Center Sophia Children's Hospital, Rotterdam, Netherlands
700    1_
$a García-Romero, Ruth $u Hospital Universitario Miguel Servet, Saragossa, Spain
700    1_
$a Medina, Enrique $u Hospital, 12 de Octubre, Madrid, Spain
700    1_
$a Sánchez, César $u Hospital Gregorio Marañón, Madrid, Spain
700    1_
$a Velasco, Marta $u Hospital Universitario Niño Jesús, Madrid, Spain
700    1_
$a Vicente, Saioa $u Hospital Universitario Ramon y Cajal, Madrid, Spain
700    1_
$a Wilson, David C $u Child Life and Health, University of Edinburgh, Edinburgh, UK
700    1_
$a Naik, Sandhia $u The Royal London Children's Hospital, Barts Health NHS Trust, London, UK
700    1_
$a Hradsky, Ondrej $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Cococcioni, Lucia $u Great Ormond Street Hospital, London, UK
700    1_
$a Martin-de-Carpi, Javier $u Hospital Sant Joan de Déu, Barcelona, Spain
773    0_
$w MED00009638 $t European journal of pediatrics $x 1432-1076 $g Roč. 183, č. 8 (2024), s. 3253-3262
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38700692 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110632 $b ABA008
999    __
$a ok $b bmc $g 2202052 $s 1231559
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 183 $c 8 $d 3253-3262 $e 20240503 $i 1432-1076 $m European journal of pediatrics $n Eur J Pediatr $x MED00009638
LZP    __
$a Pubmed-20241015
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace